title: Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study.
abstract: OBJECTIVE
  To examine trends in disease progression and survival among patients enrolled in the Swiss HIV cohort study during 1988-96 and to assess the influence of new antiretroviral combination therapies.
  
  
  METHODS
  Prospective multicentre study, with follow up visits planned at six monthly intervals.
  
  
  METHODS
  Seven HIV units at university centres and cantonal hospitals in Switzerland.
  
  
  METHODS
  3785 men (mean age 35.0 years) and 1391 women (30.3 years) infected with HIV. 2023 participants had a history of intravenous drug misuse; 1764 were men who had sex with men; 1261 were infected heterosexually; and 164 had other or unknown modes of transmission. 601 participants had had an AIDS defining illness.
  
  
  RESULTS
  During more than 15,000 years of follow up, there were 1456 first AIDS defining diagnoses and 1903 deaths. Compared with those enrolled during 1988-90, the risk of progression to a first AIDS diagnosis was reduced by 18% (relative risk 0.82 (95% confidence interval 0.73 to 0.93)) among participants enrolled in 1991-2, by 23% (0.77 (0.65 to 0.91)) among those enrolled in 1993-4, and by 73% (0.27 (0.18 to 0.39)) among those enrolled in 1995-6. Mortality was reduced by 19% (0.81 (0.73 to 0.90)), 26% (0.74 (0.63 to 0.87)), and 62% (0.38 (0.25 to 0.97)) respectively. Compared with no antiretroviral treatment, the risk of an initial AIDS diagnosis after CD4 lymphocyte counts fell to < 200 cells x 10(6)/1 was reduced by 16% (0.84 (0.73 to 0.97)) with monotherapy, 24% (0.76 (0.63 to 0.91)) with dual therapy, and 42% (0.58 (0.37 to 0.92)) with triple therapy. Mortality was reduced by 23% (0.77 (0.68 to 0.88)), 31% (0.69 (0.60 to 0.80)), and 65% (0.35 (0.20 to 0.60)) respectively.
  
  
  CONCLUSIONS
  The introduction of antiretroviral combination therapies outside the selected patient groups included in clinical trials has led to comparable reductions in disease progression and mortality.
authors.affiliation: Department of Social and Preventive Medicine, University of Berne, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Egger
authors.forename: B
authors.initials: B
authors.lastname: Hirschel
authors.forename: P
authors.initials: P
authors.lastname: Francioli
authors.forename: P
authors.initials: P
authors.lastname: Sudre
authors.forename: M
authors.initials: M
authors.lastname: Wirz
authors.forename: M
authors.initials: M
authors.lastname: Flepp
authors.forename: M
authors.initials: M
authors.lastname: Rickenbach
authors.forename: R
authors.initials: R
authors.lastname: Malinverni
authors.forename: P
authors.initials: P
authors.lastname: Vernazza
authors.forename: M
authors.initials: M
authors.lastname: Battegay
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009705:Nucleosides / Q000627:therapeutic use*; D011446:Prospective Studies; D011480:Protease Inhibitors / Q000627:therapeutic use*; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D009705:Nucleosides; D011480:Protease Inhibitors; D015215:Zidovudine